Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desflurane + remifentanil is a combination anesthetic regimen utilized for the maintenance of general anesthesia. Desflurane is a volatile, inhalational methyl ethyl ether anesthetic that acts as a positive allosteric modulator of GABA-A and glycine receptors and an antagonist of NMDA receptors, primarily providing hypnosis and muscle relaxation. Remifentanil is a potent, ultra-short-acting synthetic mu-opioid receptor agonist that provides intense intraoperative analgesia. This specific combination is frequently used in clinical research, such as the trial conducted by Bakirkoy Dr. Sadi Konuk Research and Training Hospital, as a standard-of-care comparator for evaluating alternative maintenance strategies like dexmedetomidine. The regimen is characterized by rapid onset and offset of action, allowing for precise control of anesthetic depth and fast postoperative recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desflurane + remifentanil (Bakırköy Dr. Sadi Konuk Research and Training Hospital).